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Background: Recent evidence suggests that vascular endothelial growth factor-C (VEGF-C)- dependent tumour
production promotes lymphangiogenesis, while membrane-type matrix 1 metalloproteinase (MT1-MMP) is involved
in the critical steps leading to carcinogenesis. However, the role of MT1-MMP in lymphangiogenesis and lymphatic
metastasis remains poorly understood. In the present study, we investigated the relationship between MT1-MMP
and VEGF-C in human breast cancer and correlated MT1-MMP and VEGF-C expression with lymphangiogenesis and
prognosis.
Methods: MT1-MMP and VEGF-C levels were compared in five breast carcinoma cell lines. We used a membrane
invasion assay to assess the effect of MT1-MMP and VEGF-C expression, as well as anti-MT1-MMP and VEGF-C
antibodies, on cancer cell invasion. We further assessed MT1-MMP and VEGF-C immunoreactivity and lymph vessels
in a cohort of human breast cancer specimens (n = 106) and associated MT1-MMP and VEGF-C expression with
clinicopathological parameters, such as lymphatic vessel density (LVD), and patient prognosis.
Results: MT1-MMP and VEGF-C expression differed among the five breast cancer cell lines and MT1-MMP and
VEGF-C expression were correlated with tumour cell invasion. VEGF-C mRNA expression levels and invasive activity
of MDA-MB-231 cells was inhibited by an anti-MT1-MMP antibody in a concentration-dependent manner. A
significant correlation was found between the expression of MT1-MMP and VEGF-C in breast cancer patient samples
and elevated MT1-MMP and VEGF-C expression was associated with higher LVD, lymph node metastasis, cancer
stage, and a decline in overall survival rates.
Conclusions: Our data demonstrate that MT1-MMP expression is closely correlated with VEGF-C expression, and
that MT1-MMP promotes lymphangiogenesis by up-regulating VEGF-C expression in human breast cancer. Thus,
elevated MT1-MMP may serve as a significant prognostic factor in breast cancer.
Keywords: Membrane-type matrix 1 metalloproteinases, Vascular endothelial growth factor-C, Lymphangiogenesis,
Metastasis, Breast cancerBackground
Breast cancer invasion and metastasis is a complex process
that begins with degradation of the basement membrane
by multiple proteinases. The matrix metalloproteinases
(MMPs) are one of the families of enzymes that mediate
this process as they are capable of cleaving the extracellular
matrix (ECM). Matrix 1 metalloproteinase (MT1-MMP) is
particularly significant [1] as it directly degrades a number
of ECM macromolecules, including collagen types I, II, III,* Correspondence: yechsh2012@hotmail.com
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reproduction in any medium, provided the orlaminins-1 and −5, fibronectin, vitronectin, fibrin and
aggrecan [2,3]. MT1-MMP can also degrade the ECM
indirectly by activating pro-MMP-2 on the cell surface
[4]. MMP-2 activation is an important step for cancer
invasion because this enzyme degrades type IV collagen, a
major component of the basement membrane that is a
barrier to invading cells [5]. In addition to degrading the
ECM barrier to make a path, shedding of CD44 and
syndecan-1 from the cell surface by MT1-MMP enhances
cancer cell migration and invasion. Thus, accumulating
evidence indicates that MT1-MMP is a critical factor for
tumour invasion and metastasis [6].. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and























































Figure 1 The correlation between MT1-MMP and VEGF-C
expression in human breast cancer cells. (a) MT1-MMP and VEGF-C
mRNA expression. (b) MT1-MMP and VEGF-C protein expression.
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http://www.cancerci.com/content/13/1/98Metastasis to regional lymph nodes via the lymphatic
vessels is the predominant pattern of metastasis in breast
cancer. Although the biochemical mechanisms are not
well understood, the new lymphatic capillaries formed
via lymphangiogenesis play a critical role in breast cancer
lymphatic metastases. However, little is known about
lymphangiogenesis due to the lack of markers with which
to isolate and study lymphatic endothelium. Recently, this
has been overcome after the identification of vascular endo-
thelial growth factor C (VEGF-C) as a lymphangiogenic
factor. VEGF-C is synthesised as propeptide, activated
by proteolysis to form a high-affinity ligand that binds
to the extracellular domain of vascular endothelial
growth factor receptor 3 (VEGFR-3), which is predomin-
antly expressed on lymphatic endothelia, and induces
tyrosine phosphorylation of VEGFR-3. Thus, VEGF-C
promotes intratumoural lymphangiogenesis and lymphatic
metastasis in tumours [7].
Lymphangiogenesis is similar to angiogenesis in that it
is a process of lymphatic endothelial cell (LEC) activation
and proliferation, as well as the migration of newly formed
capillaries through the physical barrier of the ECM to
form the lymphatic vascular system. This process re-
quires degradation of the interstitial matrix, which is
the major role of MMPs such as MT1-MMP. We
hypothesised that MT1-MMP also plays an important
role in lymphangiogenesis through an interaction with
VEGF-C. In this study, we investigated VEGF-C and
MT-MMP levels in five breast carcinoma cell lines and
correlated these levels with the invasive activity of breast
cancer cells. Moreover, we examined the correlation be-
tween VEGF-C and MT1-MMP expression and compared
these results with breast cancer tumour aggressiveness,
clinicopathological features of breast cancer patients, and
patient outcomes. Our findings suggest that VEGF-C and
MT1-MMP expression is closely correlated and affects
the prognosis of breast carcinomas, providing new insight
into their effects during invasion and metastasis of breast
cancer.
Results
Correlation between MT1-MMP and VEGF-C in breast
cancer cell lines
We used real-time RT-PCR to determine whether VEGF-C
or MT1-MMP mRNA expression levels differed markedly
among five breast cancer cell lines and correlated
mRNA expression changes with protein levels measured
by enzyme-linked immunosorbent assay (ELISA). MDA-
MB-231 and MCF-7ADR cell lines had higher expression
levels of VEGF-C and MT1-MMP, while neither MT1-
MMP mRNA nor protein expression was detected in
MCF-7 cells. VEGF-C mRNA expression correlated
well with MT1-MMP mRNA expression (r = 0.914,
P = 0.03; Figure 1a), and a similar correlation was foundbetween the protein expression of VEGF-C and MT1-MMP
(r = 0.945, P = 0.02; Figure 1b).
Effects of MT1-MMP and VEGF-C on invasive phenotype
of tumour cells
We found a statistically significant correlation between
MT1-MMP mRNA expression in five breast cancer cell
lines and the number of invasive tumour cells (r = 0.984.
P = 0.002). VEGF-C mRNA expression was also closely
associated with the number of invasive tumour cells
(r = 0.979, P = 0.004).
The invasive activity of MDA-MB-231 cells into re-
constituted basement membrane components was inhibited
by 0, 4, 8, or 12 μg/ml anti-MT1-MMP antibody in a
concentration-dependent manner. Moreover, RT-PCR
showed that treatment of MDA-MB-231 with an anti-
MT1-MMP antibody resulted in a concentration-dependent
decrease in VEGF-C mRNA expression levels. An anti-
VEGF-C antibody also inhibited the invasive activity of
MDA-MB-231 cells, but did not affect MT1-MMP
mRNA expression levels.
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We assessed MT1-MMP and VEGF-C expression in
samples from breast cancer patients. In normal mammary
epithelial cells, we did not observe immunostaining for
MT1-MMP and VEGF-C. However, diffuse cytoplasmic
staining for VEGF-C protein was seen in tumour cells,
while distinct tumour cell membrane staining of MT1-
MMP was observed. We defined positive staining as im-
munoreactivity in >10% of the carcinoma cells [8]. Of
the 106 breast cancer specimens, 55 (58.1%) had positive
staining for VEGF-C and 66 (62.3%) for MT1-MMP. A
significant correlation was found between the expression
of VEGF-C and MT1-MMP (r = 0.458, P < 0.001).
Correlation between MT1-MMP, VEGF-C expression
and clinicopathological features
We correlated the expression of MT1-MMP and VEGF-C
with clinicopathological features of breast cancer patients
(Table 1). Immunoreactivity of MT1-MMP was strongly
correlated with clinical stage and axillary lymph node
metastasis. VEGF-C expression was also strongly correlated





T1 14 (60.9%) 9 (39.1%) 0.
T2 30 (51.7%) 28 (48.3%)
T3 7 (41.2%) 10 (58.8%)
T4 8 (100%)
N
N0 25 (67.6%) 12 (32.4%) 0.
N1 21 (45.7%) 25 (54.3%)
N2 5 (21.7%) 18 (78.3%)
Stage
I 7 (77.8%) 2 (22.2%) 0.
II 39 (54.2%) 33 (45.8%)
III 5 (20.0%) 20 (80.0%)
ER
Positive 21 (35.0%) 39 (65.0%) 0.
Negative 30 (65.2%) 16 (34.8%)
PR
Positive 27 (42.2%) 37 (57.8%) 0.
Negative 24 (57.1%) 18 (42.9%)
Her2
Positive 24 (42.1%) 33 (57.9%) 0.
Negative 27 (55.1%) 22 (57.9%)There was also a close association between VEGF-C,
MT1-MMP expression and lymphatic vessel density.Correlation between MT1-MMP, VEGF-C expression
and patient outcome
Of the 106 patients examined in this study, 42 (39.6%)
died due to relapse of the disease during the follow-up
period. The overall survival rates for the 66 patients with
positive MT1-MMP tumour staining were significantly
lower than that of 40 patients with negative MT1-MMP
staining (P = 0.0002), while the prognosis of 55 patients
with positive VEGF-C tumour staining was poorer than
with negative VEGF-C staining (P = 0.0001). Patients with
tumours simultaneously positive for MT1-MMP and
VEGF-C had the lowest overall survival rates. In contrast,
patients with negative MT1-MMP and VEGF-C tumour
expression had the highest survival rates (P = 0.0001).
There was no difference in the clinical outcome between
patients with positive MT1-MMP and negative VEGF-C
tumour expression or patients with negative MT1-MMP
and positive VEGF-C tumour expression.on and the clinicopathological features of 106
MT1-MMP expression
P Positive Negative P
023 11 (47.8%) 12 (52.2%) 0.247
23 (39.7%) 35 (60.3%)
5 (29.4%) 12 (70.6%)
1 (12.5%) 7 (87.5%)
002 23 (62.2%) 14 (37.8%) <0.001
15 (32.6%) 31 (67.4%)
2 (8.7%) 21 (91.3%)
002 6 (66.7%) 3 (33.3%) <0.001
32 (44.4%) 40 (55.6%)
2 (8.0%) 23 (92.0%)
002 41 (68.3%) 19 (31.7%) 0.1409
25 (54.3%) 21 (45.7%)
132 43 (67.2%) 21 (32.8%) 0.1967
23 (54.8%) 19 (45.2%)
181 37 (64.9%) 20 (35.1%) 0.5440
29 (59.2%) 20 (40.8%)
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Tumour invasion and metastasis are critical steps in
determining the aggressive phenotype of human cancers
and are the major causes of cancer deaths. It is well
established that MT1-MMP can increase breast cancer
cell migration, invasion and metastasis through several
mechanisms including dissolving the basement membrane
[9], cleavage of ECM components such as laminin 5 or
type IV collagen [10,11], facilitating multicellular strand
formation [12], and processing of cell adhesion molecules
such as CD44 [13,14] and integrin subunits [15,16]. In our
study, a positive correlation between MT1-MMP protein
expression in five breast cancer cell lines and the number
of invasive tumour cells showed that higher expression
levels of MT1-MMP were associated with increased cell
invasion, consistent with previous reports [17-19].
Promotion of tumour metastasis by VEGF-C is a
consequence of tumour lymphangiogenesis via activated
VEGFR-3, which is located on lymphatic endothelial cells
[20]. In the present study, we showed that higher ex-
pression levels of VEGF-C correlated with increased
cell invasion in breast cancer cell lines and that antibody
inhibition of VEGF-C resulted in reduced tumour cell
invasive activity. These results demonstrated that VEGF-C
promotes breast cancer metastasis by inducing lymp-
hangiogenesis, as well as enhancing cancer cell mobility
and invasiveness. Greater baseline invasion of cancer cell
lines that express high levels of VEGF-C is consistent with
published reports [21] in lung cancer cells lines, breast
cancer cell lines [22] and head and neck cancer cell lines
[23]. Recent studies show that VEGFR-3 is expressed on
tumour cells in a variety of human malignancies, including
non-small cell lung cancer tumours [24,25], breast cancer
[26], colorectal adenocarcinoma [27,28], head and neck
carcinomas [29,30], and prostate carcinoma [31]. These
studies indicate that tumour cell expression of VEGFR-3
supports VEGF-C autocrine signalling, which promotes
tumour cell invasion and motility in cancer. The mecha-
nisms responsible for this may include activation of the
p38 mitogen-activated protein kinase (MAPK) pathway by
the VEGF-C/Flt-4 axis [21], which mediates cell migration
and invasion in various cancer cells [32,33].
Although many studies of the roles of MT1-MMP and
VEGF-C in malignancies have been reported, the clini-
copathological significance of MT1-MMP and VEGF-C
in human tumours is still a subject of debate. In breast
cancer, several studies clearly demonstrate a significant
association between high MT1-MMP expression, positive
lymph node status, and a poor prognosis for disease-free
survival (DFS) and overall survival (OS) [34-38]. Other
studies report a negative relationship between MT1-MMP
expression and lymph node involvement or its use as a
useful prognosticator in breast cancer [35-37,39,40].
The majority of studies have demonstrated a significantassociation between VEGF-C expression and lymph node
metastasis or a poor prognosis in breast cancer [41-49],
while others failed to relate VEGF-C expression to positive
lymph node status and a poor prognosis in [50-53]. This
discrepancy may lie in the failure to use standardised
methods of collecting and analysing data, as well as the
use of different antibodies.
In our study, MT1-MMP and VEGF-C overexpression
were both significantly associated with lymph node
metastasis and a poor prognosis for DFS and OS.
Those patients with negative MT1-MMP and VEGF-C
had the largest DFS and OS rates. Little is known about
the mechanism of metastasis via the lymphatic vessels. The
simple explanation is that lymphangiogenesis in breast
cancer increases the contact area between invading tumour
cells and the lymphatic endothelium. In addition, lymph-
atic endothelial cells might attract tumour cells by secret-
ing chemokines that actively promote lymphatic metastasis
[54,55]. In our study, elevated MT1-MMP expression was
positively associated with LVD, suggesting that MT1-MMP
promotes the formation of lymphatic vessels.
During lymphatic vessel formation, LECs send long
filopodia towards the VEGF-C-producing tumour tissues
and form tumour-directed vascular sprouts [56]. We
presume that the process of lymphangiogenesis must
consist of the following steps: (i) LEC proliferation, (ii)
LEC migration and ECM degradation [57], (iii) LEC
sprouting and invading into ECM, (iv) capillary lumen
formation. Thus, degradation of matrix proteins is a
critical step in lymphangiogenesis. Many specific pro-
teolytic enzymes are involved in this degradation process.
MMPs are a large family of proteolytic enzymes that
play a key role in the degradation of ECM [57]. New
data show that the MT1-MMP is a major modifier of
the pericellular environment. It is well established that
degradation of the basement membranes is an essential
requirement for the formation of new vessels and MT1-
MMP is a key mediator of matrix degradation during
the angiogenic response [58], suggesting that MT1-MMP
plays a role in lymphangiogenesis in human breast can-
cer [59]. Our study further shows that MT1-MMP ex-
pression was well correlated with VEGF-C expression
in breast cancer cells, and significantly correlated in
breast tumours. Our results are consistent with a report
that elevated MT1-MMP expression was associated
with elevated VEGF-C in angiogenesis [58]. Further-
more, we found that inhibition of MT1-MMP expres-
sion in breast cancer cell lines resulted in a decrease
in VEGF-C expression in a concentration-dependent
manner. These findings imply that MT1-MMP affects
lymphangiogenesis by regulating VEGF-C expression.
Therefore, MT1-MMP is an important factor involved
in lymphangiogenesis and results in higher lymph vessel
density (LVD).
Yao et al. Cancer Cell International 2013, 13:98 Page 5 of 9
http://www.cancerci.com/content/13/1/98Conclusions
In conclusion, our study reveals that MT1-MMP and
VEGF-C enhance the invasive potential of breast cancer
cells in vitro and have prognostic value for breast cancer
patients. Both MT1-MMP and VEGF-C were positively
associated with LVD and lymph node metastasis, and
MT1-MMP may promote lymphangiogenesis by up-
regulating VEGF-C expression in human breast cancer.
Further studies should investigate the mechanisms




Human breast adenocarcinoma cells lines (MCF-7, MDA-
MB-453, MDA-MB-435, MCF-7ADR, MDA-MB-231)
were stored in our laboratory. All cells were cultured
in Dulbecco’s modified Eagle’s medium (DMEM) sup-
plemented with penicillin, streptomycin, 50 ng/ml ascorbic
acid and 10% foetal calf serum (FCS) (Gibco BRL, Grand
Island, NY, USA). Cells were maintained in a humidified
incubator at 37°C with 5% CO2. The absence of myco-
plasma was confirmed using the Genprobe kit (Gen-Probe,
San Diego, CA, USA).
Real-time RT-PCR assessment of MT1-MMP and VEGF
mRNA expression
The expression of MT1-MMP and VEGF-C transcripts
was determined using real-time quantitative PCR. Briefly,
total RNA was extracted using TRIzol reagent (Invitrogen,
Grand Island, NY, USA) according to the manufacturer’s
instructions. Total RNA (1 μg) was reverse-transcribed
into single-stranded cDNA with oligo-dT18 primer and
SuperScript II reverse transcriptase (Invitrogen). Amplifica-
tion of MT1-MMP, VEGF-C and glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) as an internal control in
each reaction was carried out by polymerase chain reaction
(PCR) with the following primers: MT1-MMP, 5′-CC
TGCATCCATCAATACTACTGC-3′ (forward) and 5′-GC





C-3′ (reverse). Primers were used at a final concentration
of 0.5 μM. The reaction mixture was first denatured at 95°C
for 10 min followed by amplification at 95°C for 1 min,
55°C for 1 min, and 72°C for 1 min for 30 cycles, and by
72°C for 10 min. PCR products were visualised on a 2%
agarose gel containing 1 μg/mL ethidium bromide. To
evaluate the mRNA expression levels of MT1-MMP
and VEGF-C, the ratios of MT1-MMP and VEGF-C
GAPDH mRNA expression were measured by real-time
quantitative PCR using a Light Cycler system and reagents(Roche Molecular Diagnostics) with the double-stranded
DNA binding dye, SYBR Green 1, according to the pro-
cedure provided by the manufacturer. Standard curves
were prepared for both the target gene (MT1-MMP
and VEGF-C) and the internal control (GAPDH) by
amplifying four logarithmic dilutions of plasmid containing
the target fragment as templates. Standard dilutions
were optimised to cover the relevant concentration
range of target and reference RNA in the cell. The
quantities of MT1-MMP and VEGF-C were determined
from the standard curve and divided by the quantity of
the GAPDH internal control. The quantities of MT1-MMP
and VEGF-C were expressed as a fold differences relative
to GAPDH from three experiments in duplicate.
MT1-MMP activity assay
Cells were plated onto 15-cm plastic dishes and grown to
confluence. Plasma membrane preparations were collected
with a cell scraper, and suspended in 1-ml ice-cold
phosphate-buffered saline (PBS) containing protease
inhibitors. The lysates were further sonicated for 5 s, and
the membranes pelleted by centrifugation at 14,000 rpm
for 30 min at 4°C. Pelleted membranes were washed once
and resuspended in 0.5-ml complete PBS. Protein con-
centrations were determined with a bicinchoninic acid
reagent, and samples were diluted with complete PBS
to obtain starting concentrations of 1 mg/ml. The MT-
MMP activity assay was performed according to the
manufacturer’s protocol (Chemicon, Massachusetts, USA).
Briefly, varying dilutions of the starting membrane prepara-
tions were APMA-activated and incubated for 1 h at 37°C
with the MT-MMP peptide substrate (MCA-Pro-Leu-Gly-
Leu-Dpa-Ala-Arg-NH2) in a 96-well plate, and read the
plate on a fluorometric plate reader using a 325 nm excita-
tion and 395 nm emission filters. Standard curves with
the control peptide and MT1-MMP positive control
were generated to determine the appropriate sample
dilution at which the values fell in the middle of the
standard curves. The experiments were completed in
triplicate and repeated once.
ELISA for VEGF-C
Concentrations of VEGF-C in the medium of the cultured
tumour cells were determined using a VEGF-C ELISA kit,
as described in the protocol provided by the manufacturer
(Bender MedSystems, San Diego, CA, USA). Briefly, cell
culture medium was diluted 50-fold with sample diluent
and added into wells of a microwell plate coated with
anti-VEGF-C polyclonal antibody and incubated for 2 h at
room temperature. Biotin-conjugated polyclonal VEGF-C
antibody was added and the plate incubated for 1 h at room
temperature. The plate was washed and streptavidin-HRP
added. Following incubation, unbound streptavidin-HRP
was removed during a wash step, and the colour reagent
Table 2 Patients’ characteristics






















IDC = infiltrating ductal carcinoma.
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terminated by addition of stop solution and absorbance
is measured at 450 nm in an Elx808IU Ultra Microplate
Reader (BIO-TEK Instruments, Inc., Winooski, Vermont,
USA). A standard curve was constructed using the VEGF-C
protein standard provided in the kit. Generally, the samples
were analysed using different dilutions in triplicate.
Membrane invasion culture system assay
The membrane invasion culture system chamber was used
to measure in vitro invasiveness of the breast cancer cells.
Briefly, transwell inserts (Corning, Union City, CA, USA)
with 8 μm pores were uniformly coated with 50 μg of
Matrigel (Becton Dickinson, San Jose, CA, USA) and
air-dried before being rehydrated. Single-tumour-cell
suspensions, prepared after trypsinisation, were seeded
into the upper wells at a concentration of 1 × 105 per
well. After a 24-h incubation in a humidified incubator
at 37°C with 5% CO2, the inserts were fixed in methanol
and stained for 5 min with eosin followed by 5 min with
haematoxylin. The cells on the upper surface of the inserts
were wiped away with a cotton swab. The cells that had
migrated through the matrix and adhered to the lower
surface of the inserts were counted as nine separate fields
at 40× magnification. Each cell line was tested at least
twice and within a single experiment, each assay was
performed in quadruplicate.
Effects of anti–VEGF-C and anti–MT1-MMP on the invasive
phenotype of breast cancer cells
The effects of an anti-MT1-MMP antibody (Chemicon,
Massachusetts, USA) and anti-VEGF-C antibody (Santa
Cruz Biotechnology, Dallas, Texas, USA) on the invasive
and proteolytic activity of tumour cells were examined
using the membrane invasion assay. Briefly, log-phase
cell cultures of MDA-MB-231 were harvested. A 200-μL
cell suspension was added to transwell inserts and incu-
bated with anti-MT1-MMP antibody at concentrations
of 0, 4, 8, or 12 μg/ml for 24 h. Invasive cells were
counted as described above. VEGF-C mRNA levels in
cells incubated with various amounts of anti-MT1-MMP
antibody were analysed by real-time RT-PCR as described
above. Similarly, the effects of anti-VEGF-C antibody on
invasive activity and MT1-MMP mRNA expression were
also examined.
Patients and tissue samples
Formalin-fixed, paraffin-embedded samples obtained from
106 invasive ductal carcinomas and normal tissues from
benign breast disease procedures free from pathological
changes (n = 43) were retrieved from the pathology
files of Nanfang Hospital, Southern Medical University
(Guangzhou, China). All breast cancer patients underwent
mastectomy with an axillary dissection during 2004 andnone received pre-operative radiation or chemotherapy.
The patients with histologically positive axillary lymph
nodes or a primary tumour > 1 cm in diameter received
post-operative chemotherapy. All patients were treated
with adjuvant anti-oestrogen therapy if oestrogen receptor
or progesterone receptor. All women were followed-up
after surgical treatment at 6-month intervals for a mean
period of 71.41 months. All patients provided informed
consent according to a protocol approved by the ethics
committee of the institute. Details of breast cancer patients
are provided in Table 2.
Immunohistochemical staining for VEGF-C, MT1-MMP
and D-20
To identify the expression of MT1-MMP and VEGF-C in
the breast cancer tissue specimens, immunohistochemical
analysis was performed. Briefly, paraffin-embedded breast
cancer samples were cut into 4-μm sections. Slides were
incubated for 12 h at 37°C, de-waxed in a histological
clearing agent and hydrated. Endogenous peroxidase activ-
ity was blocked by incubation in 3% hydrogen peroxide for
15 min. Non-specific binding was prevented by incubation
in 1.5% normal rabbit serum (VEGF-C) or 3% normal
mouse serum (MT1-MMP) for 15 min in a humidified
chamber in PBS. Slides were incubated with anti-VEGF-C
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Oncogene, Cambridge, MA, USA) for 60 min at room
temperature. The primary antibody was detected using
a biotinylated horse anti-rabbit (VEGF-C) or horse
anti-mouse (MT1-MMP) secondary antibody for 30 min
at room temperature and the peroxidase was introduced
using a streptavidin conjugate. The slides were washed
thoroughly with PBS between each stage in the procedure.
The antibody reaction was visualised using a fresh substrate
solution containing an aminoethyl carbazole substrate
kit (Sigma, St. Louis, MO, USA). The sections were
counterstained with haematoxylin, dehydrated and mounted
in glycerol–vinyl–alcohol. For the negative controls, the
primary antibody was replaced with mouse IgG.
A monoclonal mouse anti-human D2-40 antibody
(Zymed, Grand Island, NY, USA) was used for the
staining of lymphatic vessels. The D2-40 antibody de-
tects a fixation-resistant epitope on a 40 kDa O-linked
sialoglycoprotein expressed in lymphatic endothelium
but not blood vessels, and can be used to assess
lymphangiogenesis specifically in conventionally processed
formalin-fixed and paraffin-embedded tissue specimens
[60,61]. The procedure for immunohistochemical staining
of D2-40 is similar to that for MT1-MMP and VEGF-C.
Sections from a previously studied case of tonsilla known
to express D2-40 were used as positive controls.
Two pathologists who were unaware of the clinical
data evaluated the immunohistochemical staining. To
evaluate MT1-MMP and VEGF-C protein expression, the
results were graded as follows; (+), >10% of the neoplastic
cells were stained; (±), <10% of the neoplastic cells were
stained; (−), neoplastic cells were not completely stained.
In this study, (−) and (±) were classified as negative.
Lymphatic vessel density (LVD) was determined as
suggested by Weidner et al. [62]. The immunostained
sections were scanned by light-microscopy at low magnifi-
cation (40×) and the areas of tissue with the greatest num-
ber of distinctly highlighted microvessels (‘hot spots’) were
selected. LVD was then determined by counting all immu-
nostained vessels at a total magnification of (200×) from
five areas for each case.Statistical analysis
All statistical calculations were carried out using the
SPSS statistical software. The relation between two
different values was evaluated using the Pearson cor-
relation coefficient. Correlations between VEGF-C, MT1-
MMP expression and clinicopathological features were
assessed by the Chi-square test. Survival curves were
generated by the Kaplan-Meier method and the dif-
ference between the curves was assessed using the
log-rank test. P < 0.05 was accepted as indicative of
statistical significance.Ethical approval
Department of Scientific Research approved the study and
the publication of our paper.
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